S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
NASDAQ:FREQ

Frequency Therapeutics (FREQ) Stock Forecast, Price & News

$0.39
+0.02 (+5.95%)
(As of 09:54 AM ET)
Compare
Today's Range
$0.37
$0.41
50-Day Range
$0.36
$0.73
52-Week Range
$0.33
$5.59
Volume
22,556 shs
Average Volume
906,619 shs
Market Capitalization
$14.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.33

Frequency Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,568.4% Upside
$6.33 Price Target
Short Interest
Healthy
1.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.07mentions of Frequency Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$36,103 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.70) to ($1.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

468th out of 969 stocks

Pharmaceutical Preparations Industry

213th out of 454 stocks


FREQ stock logo

About Frequency Therapeutics (NASDAQ:FREQ) Stock

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

FREQ Price History

FREQ Stock News Headlines

Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
Frequency Therapeutics Inc.
Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
Frequency Therapeutics (NASDAQ: FREQ)
Why Are Frequency Therapeutics Shares Surging Today
Korro Bio, Frequency Therapeutics Sign All-stock Merger Deal
FREQ - Frequency Therapeutics, Inc.
See More Headlines
Receive FREQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Frequency Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FREQ Company Calendar

Last Earnings
8/10/2023
Today
10/02/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FREQ
Fax
N/A
Employees
46
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.33
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+1,611.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-81,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$14.07 million
Book Value
$1.96 per share

Miscellaneous

Free Float
30,385,000
Market Cap
$13.51 million
Optionable
Not Optionable
Beta
0.77
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. David L. Lucchino (Age 53)
    Co-Founder, Pres, CEO & Director
    Comp: $1.02M
  • Mr. Richard J. Mitrano (Age 52)
    VP of Fin. & Operations
  • Mr. James P. Abely
    Associate Gen. Counsel & Sec.
  • Dr. John L. LaMattina Ph.D. (Age 73)
    Sr. Advisor & Member of PCA Regenerative Medicine Advisory Board













FREQ Stock - Frequently Asked Questions

Should I buy or sell Frequency Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Frequency Therapeutics in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FREQ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FREQ, but not buy additional shares or sell existing shares.
View FREQ analyst ratings
or view top-rated stocks.

What is Frequency Therapeutics' stock price forecast for 2023?

5 brokers have issued 12 month target prices for Frequency Therapeutics' stock. Their FREQ share price forecasts range from $4.00 to $8.00. On average, they anticipate the company's stock price to reach $6.33 in the next year. This suggests a possible upside of 1,611.7% from the stock's current price.
View analysts price targets for FREQ
or view top-rated stocks among Wall Street analysts.

How have FREQ shares performed in 2023?

Frequency Therapeutics' stock was trading at $3.85 at the beginning of the year. Since then, FREQ stock has decreased by 90.4% and is now trading at $0.37.
View the best growth stocks for 2023 here
.

When is Frequency Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our FREQ earnings forecast
.

How were Frequency Therapeutics' earnings last quarter?

Frequency Therapeutics, Inc. (NASDAQ:FREQ) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.14.

What other stocks do shareholders of Frequency Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Frequency Therapeutics investors own include AbbVie (ABBV), Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Pfizer (PFE), Taiwan Semiconductor Manufacturing (TSM), Atreca (BCEL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS) and Chimerix (CMRX).

When did Frequency Therapeutics IPO?

(FREQ) raised $102 million in an initial public offering on Thursday, October 3rd 2019. The company issued 6,700,000 shares at a price of $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Frequency Therapeutics' stock symbol?

Frequency Therapeutics trades on the NASDAQ under the ticker symbol "FREQ."

How do I buy shares of Frequency Therapeutics?

Shares of FREQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Frequency Therapeutics' stock price today?

One share of FREQ stock can currently be purchased for approximately $0.37.

How much money does Frequency Therapeutics make?

Frequency Therapeutics (NASDAQ:FREQ) has a market capitalization of $13.51 million and generates $14.07 million in revenue each year. The company earns $-81,580,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

How can I contact Frequency Therapeutics?

Frequency Therapeutics' mailing address is 19 PRESIDENTIAL WAY SUITE 203, WOBURN MA, 01801. The official website for the company is www.frequencytx.com. The company can be reached via phone at 781-315-4600 or via email at investorrelations@frequencytx.com.

This page (NASDAQ:FREQ) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -